Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency

Egetis Therapeutics has begun the U.S. commercial launch of EMCITATE®, the first and only FDA-approved treatment for peripheral thyrotoxicosis in adult and pediatric patients with MCT8 deficiency. The company also launched Egetis RareLink, a patient support program developed with PANTHERx Rare Pharmacy to help with medication access, education and care coordination. CEO Nicklas Westerholm said Egetis is focused on helping eligible patients receive treatment promptly; the article reports no financial results or stock-price impact.